Literature DB >> 10088597

The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38.

E Ferrero1, F Malavasi.   

Abstract

Human CD38 is a 45-kDa type II membrane glycoprotein with an intricate pattern of expression in leukocytes, although evidence is accumulating of its quite widespread expression in cells of nonvascular origin. CD38 is a member of a nascent eukaryotic gene family encoding cytosolic and membrane-bound enzymes whose substrate is NAD, a coenzyme ubiquitously distributed in nature. Functionally, CD38 is an eclectic molecule with the ability not only to catalyze but also to signal, to mobilize calcium, and to adhere to itself, to hyaluronan, and to other ligands. Interaction with CD38 on various leukocyte subpopulations has profound though diverse consequences on their life-span, but these effects seem to be independent of the enzymatic activity of the molecule. CD38 challenges our expectations of a surface molecule and we must sift through its many guises to unmask its true nature.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088597     DOI: 10.1002/jlb.65.2.151

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  13 in total

1.  Regeneration and tolerance factor: a correlate of human immunodeficiency virus-associated T-cell activation.

Authors:  T S Givens; B K DuChateau; J S Boomer; M P Westerman; A Gilman-Sachs; K D Beaman
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  The CD157-integrin partnership controls transendothelial migration and adhesion of human monocytes.

Authors:  Nicola Lo Buono; Rossella Parrotta; Simona Morone; Paola Bovino; Giulia Nacci; Erika Ortolan; Alberto L Horenstein; Alona Inzhutova; Enza Ferrero; Ada Funaro
Journal:  J Biol Chem       Date:  2011-04-08       Impact factor: 5.157

Review 3.  Tackling the cancer stem cells - what challenges do they pose?

Authors:  Diwakar R Pattabiraman; Robert A Weinberg
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

4.  Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.

Authors:  M van Oosterhout; E W N Levarht; J K Sont; T W J Huizinga; R E M Toes; J M van Laar
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

5.  CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.

Authors:  Alessia Grozio; Giovanna Sociali; Laura Sturla; Irene Caffa; Debora Soncini; Annalisa Salis; Nadia Raffaelli; Antonio De Flora; Alessio Nencioni; Santina Bruzzone
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

6.  Dynamic conformations of the CD38-mediated NAD cyclization captured in a single crystal.

Authors:  HongMin Zhang; Richard Graeff; Zhe Chen; Liangren Zhang; Lihe Zhang; Honcheung Lee; Quan Hao
Journal:  J Mol Biol       Date:  2010-12-08       Impact factor: 5.469

Review 7.  CD38 autoimmunity: recent advances and relevance to human diabetes.

Authors:  A Antonelli; E Ferrannini
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

Review 8.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

Authors:  Silvia Deaglio; Simon C Robson
Journal:  Adv Pharmacol       Date:  2011

9.  An imbalance of naive and memory/effector subsets and altered expression of CD38 on T lymphocytes in two girls with hyper-IgM syndrome.

Authors:  B T Costa-Carvalho; M A Viana; M K C Brunialti; E G Kallas; R Salomao
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 10.  Anti-CD38 autoantibodies in type? diabetes.

Authors:  Roberto Mallone; Paolo Cavallo Perin
Journal:  Diabetes Metab Res Rev       Date:  2006 Jul-Aug       Impact factor: 4.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.